Home LiteratureArticle Details
PMID: 10799583 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Variable-loop-deleted variants of the human immunodeficiency virus type 1 envelope glycoprotein can be stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits.

Journal of virology ·Vol. 74 ·No. 11 ·2000-06-00 ·Pages 5091-100

Sanders RW, Schiffner L, Master A, Kajumo F, Guo Y, Dragic T, Moore JP, Binley JM

Abstract

We have described an oligomeric gp140 envelope glycoprotein from human immunodeficiency virus type 1 that is stabilized by an intermolecular disulfide bond between gp120 and the gp41 ectodomain, termed SOS gp140 (J. M. Binley, R. W. Sanders, B. Clas, N. Schuelke, A. Master, Y. Guo, F. Kajumo, D. J. Anselma, P. J. Maddon, W. C. Olson, and J. P. Moore, J. Virol. 74:627-643, 2000). In this protein, the protease cleavage site between gp120 and gp41 is fully utilized. Here we report the characterization of gp140 variants that have deletions in the first, second, and/or third variable loop (V1, V2, and V3 loops). The SOS disulfide bond formed efficiently in gp140s containing a single loop deletion or a combination deletion of the V1 and V2 loops. However, deletion of all three variable loops prevented formation of the SOS disulfide bond. Some variable-loop-deleted gp140s were not fully processed to their gp120 and gp41 constituents even when the furin protease was cotransfected. The exposure of the gp120-gp41 cleavage site is probably affected in these proteins, even though the disabling change is in a region of gp120 distal from the cleavage site. Antigenic characterization of the variable-loop-deleted SOS gp140 proteins revealed that deletion of the variable loops uncovers cryptic, conserved neutralization epitopes near the coreceptor-binding site on gp120. These modified, disulfide-stabilized glycoproteins might be useful as immunogens.

MeSH Terms
Amino Acid Sequence Binding Sites CD4 Antigens/metabolism Disulfides/metabolism Epitopes, B-Lymphocyte Gene Products, env/genetics,metabolism Genetic Variation HIV Envelope Protein gp120/genetics,metabolism HIV Envelope Protein gp41/genetics,metabolism HIV-1/genetics,metabolism Humans Molecular Sequence Data Mutagenesis Protein Processing, Post-Translational env Gene Products, Human Immunodeficiency Virus
Chemicals
CD4 Antigens Disulfides Epitopes, B-Lymphocyte Gene Products, env HIV Envelope Protein gp120 HIV Envelope Protein gp41 env Gene Products, Human Immunodeficiency Virus gp140 envelope protein, Human immunodeficiency virus 1
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Sanders R W
Department of Human Retrovirology, Academic Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Schiffner L
Master A
Kajumo F
Guo Y
Dragic T
Moore J P
Binley J M
References (74)
74 references, click to expand
  1. Role of conserved gp41 cysteine residues in the processing of human immunodeficiency virus envelope precursor and viral infectivity.
    J Virol. 1991 Nov;65(11):6349-52 PMID: 1717722
  2. Identification of conserved residues in the human immunodeficiency virus type 1 principal neutralizing determinant that are involved in fusion.
    AIDS Res Hum Retroviruses. 1991 Oct;7(10):807-11 PMID: 1720627
  3. Functional roles of the V3 hypervariable region of HIV-1 gp160 in the processing of gp160 and in the formation of syncytia in CD4+ cells.
    Virology. 1992 Jan;186(1):313-7 PMID: 1727607
  4. Stabilization of human immunodeficiency virus type 1 envelope glycoprotein trimers by disulfide bonds introduced into the gp41 glycoprotein ectodomain.
    J Virol. 1998 Sep;72(9):7620-5 PMID: 9696864
  5. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting.
    J Virol. 1998 Nov;72(11):9092-100 PMID: 9765454
  6. Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance.
    Scand J Infect Dis. 1998;30(5):435-40 PMID: 10066039
  7. Conserved cysteine residues in the human immunodeficiency virus type 1 transmembrane envelope protein are essential for precursor envelope cleavage.
    J Virol. 1992 Feb;66(2):1207-9 PMID: 1731099
  8. Neutralizing antibodies against HIV-1 BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoproteins and boosted with homologous gp160.
    AIDS Res Hum Retroviruses. 1991 Jul;7(7):615-20 PMID: 1768463
  9. Studies on the role of the V3 loop in human immunodeficiency virus type 1 envelope glycoprotein function.
    AIDS Res Hum Retroviruses. 1992 Sep;8(9):1611-8 PMID: 1457207
  10. Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors.
    J Biol Chem. 1998 Jan 2;273(1):404-9 PMID: 9417096
  11. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.
    J Virol. 1993 Jul;67(7):3978-88 PMID: 7685405
  12. Immunochemical analysis of the gp120 surface glycoprotein of human immunodeficiency virus type 1: probing the structure of the C4 and V4 domains and the interaction of the C4 domain with the V3 loop.
    J Virol. 1993 Aug;67(8):4785-96 PMID: 7687303
  13. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1.
    J Virol. 1993 Nov;67(11):6642-7 PMID: 7692082
  14. Probing the structure of the human immunodeficiency virus surface glycoprotein gp120 with a panel of monoclonal antibodies.
    J Virol. 1994 Jan;68(1):469-84 PMID: 7504741
  15. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
    J Virol. 1994 May;68(5):3015-26 PMID: 7512157
  16. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS.
    J Virol. 1994 Jun;68(6):4031-4 PMID: 7514684
  17. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):4821-8 PMID: 7518527
  18. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization.
    AIDS Res Hum Retroviruses. 1994 Apr;10(4):359-69 PMID: 7520721
  19. Epitope mapping and topology of baculovirus-expressed HIV-1 gp160 determined with a panel of murine monoclonal antibodies.
    AIDS Res Hum Retroviruses. 1994 Apr;10(4):371-81 PMID: 8068416
  20. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
    Science. 1994 Nov 11;266(5187):1024-7 PMID: 7973652
  21. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B.
    J Virol. 1995 Jan;69(1):122-30 PMID: 7527082
  22. Epitope exposure on functional, oligomeric HIV-1 gp41 molecules.
    Virology. 1995 Jan 10;206(1):713-7 PMID: 7530400
  23. Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation.
    J Virol. 1995 Aug;69(8):4675-82 PMID: 7609032
  24. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines.
    J Virol. 1998 Feb;72(2):1552-76 PMID: 9445059
  25. The prime-boost concept applied to HIV preventive vaccines.
    AIDS. 1997;11 Suppl A:S127-37 PMID: 9451976
  26. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions.
    AIDS Res Hum Retroviruses. 1998 Jan 20;14(2):151-5 PMID: 9462925
  27. Analysis of the interaction of antibodies with a conserved enzymatically deglycosylated core of the HIV type 1 envelope glycoprotein 120.
    AIDS Res Hum Retroviruses. 1998 Feb 10;14(3):191-8 PMID: 9491908
  28. CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization.
    J Virol. 1998 Jun;72(6):4694-703 PMID: 9573233
  29. A role for carbohydrates in immune evasion in AIDS.
    Nat Med. 1998 Jun;4(6):679-84 PMID: 9623976
  30. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.
    Science. 1998 Jun 19;280(5371):1949-53 PMID: 9632396
  31. HIV. Envelope's letters boxed into shape.
    Nature. 1998 Jun 18;393(6686):630-1 PMID: 9641673
  32. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody.
    Nature. 1998 Jun 18;393(6686):648-59 PMID: 9641677
  33. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Nature. 1998 Jun 18;393(6686):705-11 PMID: 9641684
  34. Folding and assembly of viral membrane proteins.
    Virology. 1993 Apr;193(2):545-62 PMID: 8460475
  35. Legitimate and illegitimate cleavage of human immunodeficiency virus glycoproteins by furin.
    J Virol. 1993 Jun;67(6):3601-4 PMID: 8497067
  36. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.
    J Virol. 1995 Sep;69(9):5723-33 PMID: 7543586
  37. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    J Virol. 1995 Nov;69(11):6609-17 PMID: 7474069
  38. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates.
    AIDS Res Hum Retroviruses. 1995 May;11(5):533-9 PMID: 7576908
  39. A trimeric structural domain of the HIV-1 transmembrane glycoprotein.
    Nat Struct Biol. 1995 Dec;2(12):1075-82 PMID: 8846219
  40. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1996 Feb;70(2):1100-8 PMID: 8551569
  41. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein.
    J Virol. 1996 Mar;70(3):1863-72 PMID: 8627711
  42. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response.
    J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jul;12(3):213-20 PMID: 8673525
  43. HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells.
    AIDS. 1995;9 Suppl A:S117-36 PMID: 8819579
  44. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):179-83 PMID: 8906795
  45. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.
    Nature. 1996 Nov 14;384(6605):184-7 PMID: 8906796
  46. Endoprotease activities other than furin and PACE4 with a role in processing of HIV-I gp160 glycoproteins in CHO-K1 cells.
    J Biol Chem. 1997 Jan 10;272(2):1344-8 PMID: 8995442
  47. HIV-1 antibody--debris or virion?
    Nat Med. 1997 Apr;3(4):366-7 PMID: 9095159
  48. Coreceptors: implications for HIV pathogenesis and therapy.
    Science. 1997 Apr 4;276(5309):51-2 PMID: 9122710
  49. Core structure of gp41 from the HIV envelope glycoprotein.
    Cell. 1997 Apr 18;89(2):263-73 PMID: 9108481
  50. Atomic structure of the ectodomain from HIV-1 gp41.
    Nature. 1997 May 22;387(6631):426-30 PMID: 9163431
  51. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit.
    Vaccine. 1997 Jun;15(8):869-73 PMID: 9234536
  52. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off.
    J Virol. 1997 Sep;71(9):6869-74 PMID: 9261412
  53. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines.
    J Virol. 1999 Apr;73(4):2956-62 PMID: 10074145
  54. Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion.
    J Virol. 1999 May;73(5):4433-8 PMID: 10196341
  55. Variable constraints on the principal immunodominant domain of the transmembrane glycoprotein of human immunodeficiency virus type 1.
    J Virol. 1999 Jul;73(7):5698-706 PMID: 10364320
  56. Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion.
    J Virol. 1999 Jul;73(7):6089-92 PMID: 10364363
  57. Characterization of the sequence of interactions of the fusion domain of the simian immunodeficiency virus with membranes. Role of the membrane dipole potential.
    J Biol Chem. 1999 Oct 15;274(42):29951-9 PMID: 10514478
  58. A vaccine for HIV type 1: the antibody perspective.
    Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10018-23 PMID: 9294155
  59. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein.
    J Virol. 1997 Dec;71(12):9808-12 PMID: 9371651
  60. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure.
    J Virol. 2000 Jan;74(2):627-43 PMID: 10623724
  61. Modifications that stabilize human immunodeficiency virus envelope glycoprotein trimers in solution.
    J Virol. 2000 May;74(10):4746-54 PMID: 10775613
  62. The neutralizing antibody response to HIV-1: viral evasion and escape from humoral immunity.
    AIDS. 1999;13 Suppl A:S137-62 PMID: 10885772
  63. Loss of envelope antigens of HTLV-III/LAV, a factor in AIDS pathogenesis?
    Lancet. 1985 Nov 2;2(8462):1016-7 PMID: 2865493
  64. Shedding and interspecies type sero-reactivity of the envelope glycopolypeptide gp120 of the human immunodeficiency virus.
    J Gen Virol. 1986 Nov;67 ( Pt 11):2533-8 PMID: 2431105
  65. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus.
    Cell. 1988 Apr 8;53(1):55-67 PMID: 2450679
  66. Yeast KEX2 endopeptidase correctly cleaves a neuroendocrine prohormone in mammalian cells.
    Science. 1988 Jul 8;241(4862):226-30 PMID: 3291117
  67. Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.
    Proc Natl Acad Sci U S A. 1988 Dec;85(24):9580-4 PMID: 2849111
  68. Intracellular processing of the gp160 HIV-1 envelope precursor. Endoproteolytic cleavage occurs in a cis or medial compartment of the Golgi complex.
    J Biol Chem. 1990 Feb 15;265(5):2640-9 PMID: 2406237
  69. Functional contribution of cysteine residues to the human immunodeficiency virus type 1 envelope.
    J Virol. 1990 May;64(5):2250-9 PMID: 2182910
  70. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
    AIDS. 1990 Apr;4(4):307-15 PMID: 2190605
  71. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells.
    J Biol Chem. 1990 Jun 25;265(18):10373-82 PMID: 2355006
  72. Dissociation of gp120 from HIV-1 virions induced by soluble CD4.
    Science. 1990 Nov 23;250(4984):1139-42 PMID: 2251501
  73. Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization.
    J Virol. 1991 Feb;65(2):852-60 PMID: 1898972
  74. Mutations within the human immunodeficiency virus type 1 gp160 envelope glycoprotein alter its intracellular transport and processing.
    Virology. 1991 Sep;184(1):319-29 PMID: 1871974
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2000-06-00
Pages
5091-100
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC110861
Subset
IM
Grants
NIAID NIH HHS · R01 AI039420 · United States
NIAID NIH HHS · R01 AI045463 · United States
NIAID NIH HHS · R01 AI 39420 · United States
NIAID NIH HHS · R01 AI 45463 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com